Literature DB >> 3668510

Genetic analysis of vaccinia virus Lister strain and its attenuated mutant LC16m8: production of intermediate variants by homologous recombination.

F Takahashi-Nishimaki1, K Suzuki, M Morita, T Maruyama, K Miki, S Hashizume, M Sugimoto.   

Abstract

We prepared vaccinia virus variants by introducing part of the HindIII D fragment of the DNA of the parental Lister (LO) strain (temperature-resistant and forming large plaques and pocks) into the attenuated LC16m8 strain (temperature-sensitive and forming small plaques and pocks) by the use of a homologous recombination technique in vivo. Special attention was paid to the HindIII D fragment, since this fragment has an extra XhoI site in LC16m8 which is absent from LO. After HindIII D of LO was introduced as a calcium phosphate precipitate into rabbit kidney (RK13) cells which had been infected with LC16m8, five virus variants (LOTC-1 to LOTC-5) forming much larger plaques than LC16m8 were cloned. In LOTC-2, LOTC-4 and LOTC-5, the introduction of at least part of HindIII D of LO into the corresponding HindIII D region of the LC16m8 genome was apparent as judged by the disappearance of the XhoI site, whereas variants LOTC-1 and LOTC-3 retained the site. The biological characteristics of all the LOTC variants were similar to each other. Their plaque size and pock size were similar to those of LO, whereas they were rather akin to LC16m8 with regard to temperature sensitivity and neurovirulence. The present results strongly suggested that part of the HindIII D fragment was involved in determining biological characteristics affecting plaque size and pock size, but had little influence on temperature sensitivity and neurovirulence.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3668510     DOI: 10.1099/0022-1317-68-10-2705

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  8 in total

1.  An attenuated LC16m8 smallpox vaccine: analysis of full-genome sequence and induction of immune protection.

Authors:  Shigeru Morikawa; Tokuki Sakiyama; Hideki Hasegawa; Masayuki Saijo; Akihiko Maeda; Ichiro Kurane; Go Maeno; Junko Kimura; Chie Hirama; Teruhiko Yoshida; Yasuko Asahi-Ozaki; Tetsutaro Sata; Takeshi Kurata; Asato Kojima
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

2.  LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox.

Authors:  Masayuki Saijo; Yasushi Ami; Yuriko Suzaki; Noriyo Nagata; Naoko Iwata; Hideki Hasegawa; Momoko Ogata; Shuetsu Fukushi; Tetsuya Mizutani; Tetsutaro Sata; Takeshi Kurata; Ichiro Kurane; Shigeru Morikawa
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

Review 3.  Vaccinia virus vectors: new strategies for producing recombinant vaccines.

Authors:  D E Hruby
Journal:  Clin Microbiol Rev       Date:  1990-04       Impact factor: 26.132

4.  Effects and virulences of recombinant vaccinia viruses derived from attenuated strains that express the human T-cell leukemia virus type I envelope gene.

Authors:  H Shida; Y Hinuma; M Hatanaka; M Morita; M Kidokoro; K Suzuki; T Maruyama; F Takahashi-Nishimaki; M Sugimoto; R Kitamura
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

5.  The live vector approach-viruses.

Authors:  M Mackett
Journal:  World J Microbiol Biotechnol       Date:  1991-03       Impact factor: 3.312

Review 6.  LC16m8: an attenuated smallpox vaccine.

Authors:  Julie Kenner; Fiona Cameron; Cyril Empig; David V Jobes; Marc Gurwith
Journal:  Vaccine       Date:  2006-04-21       Impact factor: 3.641

7.  More cell culture passaged Camelpox virus sequences found resembling those of vaccinia virus.

Authors:  Abdelmalik I Khalafalla; Mohamed A Al Hosani; Hassan Zackaria Ali Ishag; Salama S Al Muhairi
Journal:  Open Vet J       Date:  2020-04-23

Review 8.  Vaccinia Virus: From Crude Smallpox Vaccines to Elaborate Viral Vector Vaccine Design.

Authors:  Onur Kaynarcalidan; Sara Moreno Mascaraque; Ingo Drexler
Journal:  Biomedicines       Date:  2021-11-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.